Graves眼病的诊治

doi:10.3969/j.issn.1004-583X.2016.03.003

临床荟萃 ›› 2016, Vol. 31 ›› Issue (3): 241-245.doi: 10.3969/j.issn.1004-583X.2016.03.003

Graves眼病的诊治

吕晓伟,周红

河北医科大学第二医院内分泌科,河北石家庄 050000

收稿日期:2015-11-09 出版日期:2016-03-05 发布日期:2016-04-18
通讯作者: 周红,Email:zhoubs2013@163.com
作者简介:周红，女，1967年5月生人，医学博士，主任医师，教授，硕士研究生导师，河北医科大学第二医院内分泌科副主任，河北省和石家庄市医学会内分泌分会委员。多年来从事内分泌与代谢病的临床诊治工作，近年来承担了河北省卫生厅重大项目研究并顺利完成；参与了多项国际多中心合作研究，获得2014年河北省卫计委政府资助临床医学优秀人才培养基金；在国内外期刊发表多篇研究论文，其中以第一作者发表SCI论文6篇。

Diagnosis and treatment in Graves’ ophthalmopathy

Lu Xiaowei, Zhou Hong

Department of Endocrinology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China

Received:2015-11-09 Online:2016-03-05 Published:2016-04-18
Contact: Zhou Hong, Email: zhoubs2013@163.com

摘要/Abstract

摘要： Graves眼病(GO)是Graves病最常见的一种甲状腺腺外表现,其发病机制涉及遗传、环境和自身免疫紊乱等多种因素,临床表现复杂多样,只有对GO的活动性和严重程度做出准确评估,才能选择恰当的治疗方案。活动期中、重度GO最有效的治疗方法是糖皮质激素和眶部放射,近年来也发展了一些新的治疗方法,疗效有待于进一步证实。

关键词: 甲状腺功能亢进症, 诊断, 糖皮质激素类, 放射疗法, 眼外科手术

Abstract: Graves ophthalmopathy (GO) is the most common manifestation outside thyroid. The pathogenesis of GO mainly involves in genetic, environmental elements and autoimmune disorder. The clinical features of GO are complicated and various. Only accurately evaluating its activity and severity, effective treatments are chosen. Currently, glucocorticoid treatment and orbital radiotherapy are generally indicated for moderate-to-severe GO. A few of new therapies are under investigation and hold promise for the future.

Key words: hyperthyroidism, diagnosis, glucocorticoids, radiotherapy, ophthalmologic surgical procedure

中图分类号:

R581.1

吕晓伟,周红. Graves眼病的诊治[J]. 临床荟萃, 2016, 31(3): 241-245.

Lu Xiaowei, Zhou Hong. Diagnosis and treatment in Graves’ ophthalmopathy[J]. Clinical Focus, 2016, 31(3): 241-245.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.03.003

https://huicui.hebmu.edu.cn/CN/Y2016/V31/I3/241

参考文献

[1] Lytton SD, Ponto KA, Kanitz M, et al. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy[J]. J Clin Endocrinol Metab, 2010,95(5):2123-2131.
[2] Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease[J]. J Immunol,2008,181(6):4397-4405.
[3] Kaspar M, Archibald C, De BA, et al. Eye muscle antibodies and subtype of thyroid-associated ophthalmopathy[J]. Thyroid,2002,12(3):187-191.
[4] Ohkura T, Taniguchi S, Yamada K, et al. Detection of the novel autoantibody (anti-UACA antibody) in patients with Graves’ disease[J]. Biochem Biophys Res Commun, 2004,321(2):432-440.
[5] Trisk F, Tallstedt L, Abraham-Nordling M, et al. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131[J]. J Clin Endocrinol Metab,2009,94(10):3700-3707.
[6] Daroszewski J,Pawlak E,Karabon L,et al. Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms[J]. Eur J Endocrinol,2009,161(5):787-793.
[7] Khalilzadeh O,Anvari M,Esteghamati A,et al. Genetic susceptibility to Graves' ophthalmopathy: the role of polymorphisms in anti-inflammatory cytokine genes[J]. Ophthalmic Gene,2010,31(4):215-220.
[8] Kahaly GJ. Imaging in thyroid-associated orbitopathy[J]. Eur J Endocrinol, 2001,145(2):107-118.
[9] Ajjan RA, Weetman AP. New understanding of the role of cytokines in the pathogenesis of Graves’ ophthnopathy[J]. Endocrinol Invest,2004,27(3):237-245.
[10] Smith TJ. Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid associated ophthalmopathy[J]. Thyriod, 2001,12(3):197-203.
[11] Weber KJ, Solorzano CC, Lee JK,et al. Thyroidectomy remains an effective treatment option for Graves’disease[J]. Am J Surg, 2006,191(3): 400-405.
[12] Wiersinga WM.Management of Graves' ophthalmopathy[J]. Nat Clin Pract Endocrinol Metab, 2007,3(5):396-404.
[13] Kahaly GJ, Rosler HP, Pitz S,et al. Low-versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial[J]. Clin Endocrinol Metab,2000,85(1):102-108.
[14] Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective, single-blind, randomized study[J].J Clin Endocrinol Metab, 2001,86(8):3562-3567.
[15] Tsujino K, Hirota S, Hagiwara M,et al. Clinical outcomes of orbital irradiation combined with or without systemic high-dose or pulsed corticosteroids for Graves' ophthalmopathy[J]. Int J Radiat Oncol Biol Phys, 2000,48(3):857-864.
[16] Krassas GE, Gogakos A, Boboridis K. Corticosteroids in the medical treatment of thyroid ophthalmopathy: when and how Somatostatin analogues: where we stand today[J]. Pediatr Endocrinol Rev, 2010,7( Suppl 2):204-209.
[17] Stan MN, Garrity JA, Bradley EA, et al. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy[J]. J Clin Endocrinol Metab, 2006,91(12):4817-4824.
[18] Krassas GE, Gogakos A. Thyroid-associated ophthalmopathy in juvenile Graves' disease--clinical, endocrine and therapeutic aspects[J]. J Pediatr Endocrinol Metab, 2006,19(10):1193-1206.
[19] Madaschi S, Rossini A, Formenti I, et al. Treatment of thyroid-associated orbitopathy with rituximab--a novel therapy for an old disease: case report and literature review[J]. Endocr Pract, 2010,16(4):677-685.
[20] Lee S, Tsirbas A, Goldberg RA, et al. Thiazolidinedione induced thyroid associated orbitopathy[J]. BMC Ophthalmol, 2007,7:8.
[21] 黄艳,谭兴善. 云克与糖皮质激素治疗 Graves’眼病的临床分析[J]. 医学理论与实践, 2008,21(4):448-449.

Graves眼病的诊治

Diagnosis and treatment in Graves’ ophthalmopathy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	游琪琪, 霍丽娟. 原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治进展[J]. 临床荟萃, 2024, 39(1): 84-87.
[2]	赵浩天, 李丽. 肺超声在心脏急重症疾病合并肺水肿中应用的研究进展[J]. 临床荟萃, 2023, 38(9): 832-837.
[3]	陈聪水, 李园, 陈淑芳. 重视儿童胆源性胰腺炎的中西医诊治(附1例分析)[J]. 临床荟萃, 2023, 38(8): 726-730.
[4]	沃拉孜汗·玛德尼亚提, 迪力夏提·图尔迪麦麦提, 李梦晨, 拜合提尼沙·吐尔地. 宏基因组二代测序技术在肺结核诊断中应用价值的meta分析[J]. 临床荟萃, 2023, 38(5): 389-398.
[5]	李蕾, 赵永超, 郑加香. 儿童Graves病的诊治新进展[J]. 临床荟萃, 2023, 38(5): 477-480.
[6]	黎恒楠, 黄艳, 赵亚娟, 胡桂才. 血清CTRP5与持续非卧床腹膜透析患者左室舒张功能异常的相关性及其诊断价值[J]. 临床荟萃, 2023, 38(4): 324-329.
[7]	柴春艳, 王婷. 老年高钙血症3例并文献复习[J]. 临床荟萃, 2023, 38(2): 166-169.
[8]	王军宏, 高振华, 章荣龙, 姬浩民, 赵信科, 达明绪. 1980-2021年胃癌诊断文献相关质量分析——基于Web of Science 数据库的文献计量学分析[J]. 临床荟萃, 2023, 38(12): 1117-1124.
[9]	何培华, 周幸福, 洪炜鸿, 王利纯, 刘素君, 金玉燕, 曾佳豪, 刘立昌. IgG4相关性肾病4例临床分析[J]. 临床荟萃, 2023, 38(11): 1016-1021.
[10]	刘晔, 阮桂仁, 刘晓清, 侍效春, 费贵军. 胰腺结核的诊断及鉴别诊断[J]. 临床荟萃, 2023, 38(10): 898-903.
[11]	周景坤, 杨彩虹, 冯涛, 崔华英. 半乳甘露聚糖在支气管扩张症合并肺曲霉菌病中的诊断价值[J]. 临床荟萃, 2022, 37(9): 799-803.
[12]	王珍珍, 赵仕一, 冯鸶然, 马博清. 中性粒细胞和淋巴细胞比值预测2型糖尿病患者微量白蛋白尿的价值[J]. 临床荟萃, 2022, 37(9): 808-812.
[13]	杨文, 周泽平. 二代测序技术在血管性血友病诊断中的应用[J]. 临床荟萃, 2022, 37(9): 860-864.
[14]	钟鸣, 李伟. 无症状型甲状旁腺功能亢进症的诊治进展[J]. 临床荟萃, 2022, 37(7): 648-652.
[15]	叶倩, 凌志, 刘申香, 路国涛, 殷旭东. 糖皮质激素对晚期肿瘤患者免疫疗效影响的Meta分析[J]. 临床荟萃, 2022, 37(7): 591-598.